Philip L. McCarthy, MD

Philip L. McCarthy, MD, Director, Blood & Marrow Transplant Program, Department of Medicine, Roswell Park Cancer Institute, comments on the move from doublet therapy to triplet therapy for multiple myeloma.

Triplet therapies are often a combination of a novel drug (an IMiD or proteasome inhibitor) with two other agents or an IMiD and proteasome inhibitor with steroids. McCarthy says that triplet therapy is becoming a part of the gold standard for upfront myeloma treatment.

The current thinking is moving away from doublet therapy and towards triplet therapy for myeloma

lenalidomide + bortezomib + dexamethasone

cyclophosphamide + lenalidomide + dexamethasone

cyclophosphamide + bortezomib + dexamethasone

Triplet therapy is becoming a part of the gold standard for upfront myeloma treatment

Philip L. McCarthy, MD | Authors

Articles

Triplet Therapy for Multiple Myeloma